Tadekinig alfa (Yeda Research and Development Company)

N/A

Report date: 2022/02/11 17:32:50

Base Information

Drug NameTadekinig alfa (Yeda Research and Development Company)
Drug Alias NameIL-18bp (Yeda Research and Development Company)Interleukin-18 binding protein - SeronoIL-18 binding proteinTadekinig-αr-IL-18 bp
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionInterleukin 18 inhibitors
TargetsInterleukin 18
Therapy Area/IndicationsAutoimmune DiseasesPsoriasisCrohn Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesYeda Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesYeda PharmaMerck Serono
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesPsoriasisCrohn Disease +[4] 

Other Information

ATC CodeN/A
Related LinksN/A